Form 4: Cytokinetics Director Nancy Wysenski Reports Stock and Option Awards

Director Nancy Wysenski reports the acquisition of restricted stock units and stock options in Cytokinetics, Inc.

Summary

• On May 14, 2025, Nancy Wysenski, a director of Cytokinetics Inc., reported transactions involving the company's securities.
• Wysenski acquired 7,333 restricted stock units (RSUs) and disposed of 0 shares, resulting in a total of 30,610 shares beneficially owned following the transaction.
• Additionally, Wysenski acquired 10,880 non-qualified stock options with an exercise price of $30, exercisable monthly over one year, resulting in a total of 10,880 derivative securities beneficially owned.
• The RSUs will vest on the earlier of the one-year anniversary of the grant date or the date of the issuer's annual meeting of stockholders for the subsequent calendar year, contingent upon continuous service as a director.
• The stock options will vest monthly in equal installments over a period commencing on the grant date and ending on the earlier of the one-year anniversary of the date of the grant and the date of the issuer's annual meeting of stockholders for the subsequent calendar year, contingent upon continuous service as a director.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive as it reflects standard compensation practices for a director, aligning interests with shareholders.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedules for both RSUs and stock options incentivize continued service on the board.

Future Outlook

The vesting of RSUs and stock options is contingent upon the director's continuous service, suggesting an expectation of continued involvement with the company.

Industry Context

Stock and option awards are a common form of compensation for directors in publicly traded companies, aligning their interests with shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Director compensation packages, including stock options and RSUs, are standard practice in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen also utilize similar equity-based compensation to align director interests with shareholder value.
• The vesting schedules described are typical, often tied to continued service and company performance.

Stakeholder Impact

• The equity-based compensation aims to align the director's interests with those of the shareholders, potentially leading to better corporate governance and value creation.
• Employees may view the director's equity stake as a positive sign of commitment to the company's long-term success.

Key Dates

Keywords

Cytokinetics, Director, Wysenski, Stock Options, RSUs, Form 4, Beneficial Ownership, Securities